Atria Wealth Solutions Inc. Sells 7,494 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atria Wealth Solutions Inc. decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 187,645 shares of the biopharmaceutical company’s stock after selling 7,494 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Bristol-Myers Squibb were worth $9,628,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in Bristol-Myers Squibb in the 3rd quarter valued at approximately $25,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb in the 3rd quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 200 shares in the last quarter. Legacy Financial Group LLC acquired a new position in Bristol-Myers Squibb in the 3rd quarter valued at approximately $39,000. Finally, VisionPoint Advisory Group LLC raised its holdings in Bristol-Myers Squibb by 300.5% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 553 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 8.5 %

Shares of NYSE:BMY traded down $4.14 during midday trading on Thursday, hitting $44.72. The company had a trading volume of 25,784,518 shares, compared to its average volume of 15,646,563. Bristol-Myers Squibb has a 12 month low of $44.61 and a 12 month high of $69.74. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The stock has a market cap of $90.64 billion, a price-to-earnings ratio of 11.70, a PEG ratio of 1.48 and a beta of 0.39. The firm has a fifty day simple moving average of $51.22 and a 200 day simple moving average of $51.31.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period last year, the company earned $2.05 EPS. The firm’s revenue was up 4.7% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.37%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BMY shares. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.